[Renin-angiotensin-aldosterone system inhibitors and electrolyte disturbances]

Nihon Rinsho. 2012 Sep;70(9):1536-41.
[Article in Japanese]

Abstract

Recent numerous clinical studies have suggested that the renin-angiotensin-aldosterone system (RAAS) inhibitors have beneficial effects on hypertension, cardiovascular and chronic kidney diseases (CKD). Electrolyte disorder, especially hyperkalemia, is observed after the administration of RAAS inhibitors. This review focuses on the prevalence and severity of hyperkalemia with the use of RAAS inhibitors. Clinical evidences suggest that hypertensive patients with heart failure and CKD, and patients with combination treatment of RAAS inhibition are at higher risk of hyperkalemia, and serum potassium levels should be carefully monitored.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Animals
  • Heart Failure / drug therapy
  • Humans
  • Hyperkalemia / drug therapy*
  • Hyperkalemia / metabolism
  • Kidney Failure, Chronic / drug therapy
  • Renin-Angiotensin System* / drug effects
  • Water-Electrolyte Imbalance*

Substances

  • Angiotensin-Converting Enzyme Inhibitors